PT - JOURNAL ARTICLE AU - Dubois, Julien AU - Kucharczak, Florentin AU - Mariano-Goulart, Denis AU - Paunet, Tom TI - Bone tracers for transthyretin amyloid cardiomyopathy: are [<sup>99m</sup>Tc]Tc-DPD and [<sup>99m</sup>Tc]Tc-HMDP truly equivalent? AID - 10.1101/2024.02.14.24302851 DP - 2024 Jan 01 TA - medRxiv PG - 2024.02.14.24302851 4099 - http://medrxiv.org/content/early/2024/02/17/2024.02.14.24302851.short 4100 - http://medrxiv.org/content/early/2024/02/17/2024.02.14.24302851.full AB - Background The management of transthyretin amyloid cardiomyopathy (ATTR-CM) has revolved around the scintigraphic diagnosis since the introduction of a specific treatment; however, the equivalency of the bone radiotracers remains unclear. This retrospective monocentric observational study compared [99mTc]Tc-3,3-diphosphono-1,2-propanodicarboxylic acid ([99mTc]Tc-DPD) and [99mTc]Tc-hydroxy-methylene diphosphonate ([99mTc]Tc-HMDP) for ATTR-CM diagnosis.Methods One hundred and twenty-nine patients who underwent single photon emission computed tomography (SPECT/CT) after intravenous injection of [99mTc]Tc-DPD or [99mTc]Tc-HMDP for ATTR-CM were included. The patients’ current visual Perugini grades were retrieved. Regions of interest (ROI) were measured on the heart (H) and on contralateral mediastinum (CM), and H/CM ratios were calculated.Results Although the distribution of quantitative assessments of heart to contralateral mediastinum ratios is wider with [99mTc]Tc-DPD, suggesting a trend towards improved diagnosis, no difference in Perugini grades was found between [99mTc]Tc-DPD or [99mTc]Tc-HMDP for the diagnosis of ATTR-CM in evocative/non-evocative conditions. There was no difference in ATTR-CM diagnosis between the 2 tracers with a threshold of 1.5 (p-value = 3.316*10−10 for [99mTc]Tc-HMDP and p-value = 2.59*10−15 for [99mTc]Tc-DPD).Conclusions We show in our local cohort that [99mTc]Tc-DPD and [99mTc]Tc-HMDP for amyloidosis diagnostic are equivalent for ATTR-CM diagnosis based on the Perugini grading scale. With [99mTc]Tc-DPD, a wider range of the H/CM ratio was noted, which may be considered as a better discrimination of the disease by this bone tracer. Additional research with a final diagnosis of the disease is necessary to evaluate the utility of this quantitative evaluation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors declare that they have no competing interests and that they have received no funding for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in accordance with the Helsinki Declaration and was approved by the French nuclear medicine committee for the protection of individuals (CEMEN) the 05/12/2023 and registered under the institutional review board number CEMEN-2023-04. Written informed consent was obtained by all the patients for publication and accompanying images.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.